Genpharmasec

Which are the latest news on Genpharmasec?

Why is Genpharmasec Ltd falling/rising?

As of 05-Sep, Genpharmasec Ltd's stock price is rising to 1.25, driven by a 21.36% gain over the past week compared to a decline in the Sensex. Despite a drop in investor participation, the stock's strong performance and bullish trend indicate ongoing interest among investors.

As of 05-Sep, Genpharmasec Ltd's stock price is rising, currently at 1.25, with a change of 0.01 (0.81%) upward. This positive movement can be attributed to several factors. Over the past week, the stock has significantly outperformed the benchmark Sensex, gaining 21.36% compared to the Sensex's decline of 0.97%. Additionally, the stock has shown strong performance over the past month, with a rise of 19.05% while the Sensex fell by 2.44%. <BR><BR>Moreover, Genpharmasec is trading above its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bullish trend. However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 68.43% against the 5-day average, which could be a concern for future trading activity. Despite this, the stock remains liquid enough for trading, suggesting that there is still interest among investors. Overall, the combination of recent strong performance relative to the market and favorable moving averages contributes to the stock's rising price.

Who are in the management team of Genpharmasec?

The management team of Genpharmasec includes Ulhas Narayan Deosthale (Executive Director), Rajesh Sadhwani and Sneha Sadhwani (Non-Executive Directors), Siddhesh Shankar Shende, Mayur Bharatbhai Bhatt, and Sachin Aphandkar (Independent Directors), along with Heta Shah (Company Secretary & Compliance Officer). This team combines executive leadership with independent oversight.

The management team of Genpharmasec includes the following individuals:<BR><BR>1. **Ulhas Narayan Deosthale** - Executive Director / Whole Time Director<BR>2. **Rajesh Sadhwani** - Non-Executive & Non-Independent Director<BR>3. **Sneha Sadhwani** - Non-Executive & Non-Independent Director<BR>4. **Siddhesh Shankar Shende** - Independent Non-Executive Director<BR>5. **Mayur Bharatbhai Bhatt** - Independent Director<BR>6. **Sachin Aphandkar** - Independent Director<BR>7. **Heta Shah** - Company Secretary & Compliance Officer<BR><BR>This team brings a mix of executive and independent oversight to the company.

What does Genpharmasec do?

Genpharmasec Ltd, a Micro Cap company in the Trading & Distributors industry, was incorporated in 1992 and reported net sales of 50 Cr and a net profit of 0 Cr for June 2026. The company, formerly known as Adi Rasayan Limited, has a market cap of INR 57 Cr and operates from Mumbai.

Overview: <BR>Genpharmasec Ltd operates in the Trading & Distributors industry and is classified as a Micro Cap company.<BR><BR>History: <BR>Genpharmasec Ltd was originally incorporated as a Public Limited Company on 16th November 1992 in Gujarat under the name "Adi Rasayan Limited." The company changed its name to "Genpharmasec Limited" on 27th November 2018. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 50 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 57 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.38 <BR>Return on Equity: 1.06% <BR>Price to Book: 0.87<BR><BR>Contact Details: <BR>Address: Office 104 & 105 1st Flr, Gundecha Indl Kandivali (East) Mumbai Maharashtra : 400101 <BR>Email: genericpharmasec09@gmail.com <BR>Website: http://www.genpharmasec.com

Who are the peers of the Genpharmasec?

Genpharmasec's peers include Bombay Cycle, Constronics, Safa Systems, Gautam Exim, Ganesha Ecoverse, Fortune Interntl, Danube Industrie, and Growington Vent. Most peers exhibit below-average management and growth risks, with Danube Industrie showing the highest 1-year return at 29.61% and Genpharmasec at -41.75%.

Peers: The peers of Genpharmasec are Bombay Cycle, Constronics, Safa Systems, Gautam Exim, Ganesha Ecoverse, Fortune Interntl, Danube Industrie, and Growington Vent.<BR><BR>Quality Snapshot: Below Average management risk is observed at Bombay Cycle, Safa Systems, Gautam Exim, Ganesha Ecoverse, Fortune Interntl, Genpharmasec, Danube Industrie, and Growington Vent. Good management risk is found at Constronics. Below Average growth is noted at Bombay Cycle, Safa Systems, Gautam Exim, Ganesha Ecoverse, Genpharmasec, and the rest, while Good growth is observed at Constronics and Excellent growth is seen at Growington Vent. The Capital Structure is Good at Bombay Cycle and Growington Vent, Average at Constronics, and Below Average at Safa Systems, Gautam Exim, Ganesha Ecoverse, Fortune Interntl, Genpharmasec, Danube Industrie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Danube Industrie at 29.61%, while the peer with the lowest is Gautam Exim at -31.92%. Genpharmasec's 1-year return is -41.75%, which is lower than both of these peers. Additionally, the six-month return is negative for Bombay Cycle, Safa Systems, Gautam Exim, Ganesha Ecoverse, Fortune Interntl, Genpharmasec, Growington Vent.

How big is Genpharmasec?

As of 31st August, Genpharmasec Ltd has a market capitalization of 57.00 Cr and reported net sales of 177.61 Cr with a net loss of 0.26 Cr over the latest four quarters. Shareholder's funds were 65.16 Cr and total assets were valued at 79.43 Cr as of March 2025.

As of 31st August, Genpharmasec Ltd has a market capitalization of 57.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Genpharmasec reported net sales of 177.61 Cr. However, the company experienced a loss of 0.26 Cr in net profit during this period.<BR><BR>The latest annual period for the balance sheet is March 2025, where shareholder's funds amounted to 65.16 Cr and total assets were valued at 79.43 Cr.

Should I buy, sell or hold Genpharmasec Ltd?

When is the next results date for Genpharmasec Ltd?

The next results date for Genpharmasec Ltd is 11 August 2026.

The next results date for Genpharmasec Ltd is scheduled for 11 August 2026.

Are Genpharmasec Ltd latest results good or bad?

Genpharmasec Ltd's latest results show strong revenue growth with Q4 FY26 net sales at ₹55.43 crores, a 295.65% increase year-on-year. However, significant profitability concerns arise from a 555.56% decline in net profit and reliance on non-operating income, leading to a cautious investment outlook with a "STRONG SELL" rating.

Genpharmasec Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue in Q4 FY26, with net sales reaching ₹55.43 crores, reflecting an impressive year-on-year growth of 295.65% and a sequential increase of 39.17%. This indicates strong business expansion in the trading and distribution segment.<BR><BR>However, the profitability aspect raises significant concerns. The consolidated net profit for the quarter was ₹1.23 crores, which is a staggering decline of 555.56% year-on-year. This sharp drop highlights the company's fragility in generating sustainable profits, as over half of its profit before tax came from non-operating income, raising questions about the quality and sustainability of its earnings.<BR><BR>While the operating margin improved to 3.61% from a negative margin in the previous year, it remains low and indicates inconsistent operational efficiency. Additionally, the average return on equity (ROE) over the past five years is a mere 1.03%, suggesting poor capital efficiency.<BR><BR>Overall, despite the strong revenue growth, the underlying profitability issues and heavy reliance on non-operating income lead to a negative assessment of the company's financial health. The investment outlook is cautious, with a "STRONG SELL" rating reflecting concerns about long-term earnings quality and competitive positioning.

How has been the historical performance of Genpharmasec?

Genpharmasec has experienced steady revenue growth from 25.52 Cr in Mar'23 to 33.72 Cr in Mar'25, but operating profit has fluctuated, with a recovery in profit after tax from a loss in Mar'24 to 1.23 Cr in Mar'25. The company faces challenges in managing expenses and cash flow despite overall growth.

Answer:<BR>The historical performance of Genpharmasec shows a mixed trend over the past three years, with notable fluctuations in revenue and profit metrics.<BR><BR>Breakdown:<BR>Genpharmasec's net sales have increased from 25.52 Cr in Mar'23 to 30.41 Cr in Mar'24, and further to 33.72 Cr in Mar'25, indicating a steady growth in total operating income. The total expenditure has also risen, from 25.26 Cr in Mar'23 to 30.36 Cr in Mar'24, and 33.66 Cr in Mar'25, reflecting increased costs in purchases and employee expenses. Operating profit, however, has shown variability, with a peak of 0.36 Cr in Mar'23, dropping to 0.05 Cr in Mar'24, and slightly recovering to 0.06 Cr in Mar'25. Profit before tax improved significantly from 0.28 Cr in Mar'23 to 1.88 Cr in Mar'25, while profit after tax showed a recovery from a loss of 0.17 Cr in Mar'24 to a profit of 1.23 Cr in Mar'25. The company's total assets have increased from 19.03 Cr in Mar'23 to 79.43 Cr in Mar'25, with total liabilities also rising from 19.03 Cr to 79.43 Cr in the same period. Cash flow from operating activities improved from -3.00 Cr in Mar'23 to 2.00 Cr in Mar'25, although the net cash outflow was -13.00 Cr in Mar'25, down from a net inflow of 16.00 Cr in Mar'24. Overall, while Genpharmasec has shown growth in sales and profit recovery, it faces challenges in managing expenses and cash flow.

Is Genpharmasec overvalued or undervalued?

As of August 8, 2025, Genpharmasec is considered overvalued with a PE ratio of 45.35 and negative ROCE, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -35.60%.

As of 8 August 2025, Genpharmasec's valuation grade has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 45.35, an EV to EBITDA ratio of 111.26, and a PEG ratio of 0.10. These ratios suggest that the stock is trading at a premium compared to its earnings potential, especially when considering its negative ROCE of -0.42% and a low ROE of 1.25%.<BR><BR>In comparison to its peers, Genpharmasec's valuation stands out as particularly high. For instance, Lloyds Enterprises has a PE ratio of 186.85 and MMTC has a PE ratio of 133.83, both categorized as risky, while PTC India, which is very attractive, has a PE ratio of just 8.33. This stark contrast highlights the overvaluation of Genpharmasec within its industry. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -35.60% compared to the Sensex's 2.20%, further reinforcing the notion that Genpharmasec is overvalued.

What is the technical trend for Genpharmasec?

As of May 13, 2025, Genpharmasec's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 13 May 2025, the technical trend for Genpharmasec has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and Bollinger Bands show a bearish trend on both weekly and monthly time frames. The KST is mildly bullish weekly but bearish monthly, and Dow Theory indicates a mildly bullish trend on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

Who are the top shareholders of the Genpharmasec?

The top shareholders of Genpharmasec are Sneha Sadhwani, the promoter with 16.8%, and public shareholder Yogeshkumar Rasiklal Sanghavi with 7.07%. Individual investors hold a combined 59.94% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genpharmasec include Sneha Sadhwani, who is the promoter with the highest holding at 16.8%. The highest public shareholder is Yogeshkumar Rasiklal Sanghavi, holding 7.07%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 59.94% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Genpharmasec declared dividend?

No Dividend History Available